AI
Monday, February 07, 2011 3:08:00 PM
Alert...bought NEOP.OB ($3.09) here at $3.03 & $3.08 today with 5% of portfolio. This play has pending catalysts that should be realized very soon in the month of February & into March. The volume is at 420,000 with 50 minutes left in the trading day. This company specializes in surgical oncology products.
Really good Interview with a key company executive here from the January One Med Place Conference.
http://www.onemedplace.com/database/list/cid/314
Report Here
http://www.tripointglobalresearch.com/research/NEOP/NEOP_Report_092210.pdf
Had this on my radar for a while as I traded it last year, but
have been in other plays like DEPO. I like the near-term catalysts here.
Near-term catalysts 1Q-2Q11
-Top line data from Lymphoseek NEO3-09 Phase III study in Feb.
-Presentation of detailed NEO3-09 Phase III dataset.
-Submission of Lymphoseek NDA
-FDA pre-IND Meeting for RIGScan CR49
-New IND for RIGScan to reinitiate clinical development
-Clarification of full RIGS development & registration plan with FDA and EMA
-Possible listing on major exchange
Nearing completion of NEO3-09 study in 150 subjects with breast cancer & melanoma. They expect to announce full enrollment in the study early this month. This study will confirm the concordance rate with vital blue dye and will also allow the possibility for showing superiority to vital blue dye which is important from a labeling standpoint. This could allow them the chance to make claims of superiority in the market place.
Really good Interview with a key company executive here from the January One Med Place Conference.
http://www.onemedplace.com/database/list/cid/314
Report Here
http://www.tripointglobalresearch.com/research/NEOP/NEOP_Report_092210.pdf
Had this on my radar for a while as I traded it last year, but
have been in other plays like DEPO. I like the near-term catalysts here.
Near-term catalysts 1Q-2Q11
-Top line data from Lymphoseek NEO3-09 Phase III study in Feb.
-Presentation of detailed NEO3-09 Phase III dataset.
-Submission of Lymphoseek NDA
-FDA pre-IND Meeting for RIGScan CR49
-New IND for RIGScan to reinitiate clinical development
-Clarification of full RIGS development & registration plan with FDA and EMA
-Possible listing on major exchange
Nearing completion of NEO3-09 study in 150 subjects with breast cancer & melanoma. They expect to announce full enrollment in the study early this month. This study will confirm the concordance rate with vital blue dye and will also allow the possibility for showing superiority to vital blue dye which is important from a labeling standpoint. This could allow them the chance to make claims of superiority in the market place.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
